{"id":642634,"date":"2023-03-14T20:02:01","date_gmt":"2023-03-14T20:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=642634"},"modified":"2023-03-14T20:02:01","modified_gmt":"2023-03-14T20:02:01","slug":"chronic-inflammatory-demyelinating-polyneuropathy-cidp-emerging-and-marketed-drugs-assessment-2023-updates-clinical-trials-latest-fda-ema-and-pmda-approvals-key-players-competitive-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-emerging-and-marketed-drugs-assessment-2023-updates-clinical-trials-latest-fda-ema-and-pmda-approvals-key-players-competitive-landscape_642634.html","title":{"rendered":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging and Marketed Drugs Assessment (2023 Updates)| Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Key Players, Competitive Landscape"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging and Marketed Drugs Assessment (2023 Updates)| Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Key Players, Competitive Landscape\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging and Marketed Drugs Assessment (2023 Updates)| Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Key Players, Competitive Landscape\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 10+ key pharma and biotech companies are working on 12+ pipeline drugs in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\"><em>The CIDP treatment landscape continues to evolve, and several companies are furiously working toward the development of new treatments that could potentially cure and change the treatment landscape of CIDP. Companies are focused on the development of FcRN targeting therapies for the treatment of CIDP, this shall create a positive impact on the market size of the disease in coming years.<\/em><\/p>\n<p style=\"text-align: justify;\"><em>Major pharma and biotech giants such as&nbsp;<strong>Argenx, Sanofi, Takeda,<\/strong> and others are coming up with novel therapeutic approaches that can entirely change the treatment landscape of CIDP. If launched, these emerging potential candidates could pose an adverse threat to current CIDP treatment.<\/em><\/p>\n<p style=\"text-align: justify;\">&ldquo;<strong>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Chronic Inflammatory Demyelinating Polyneuropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/18084edda215068a4449d1f6156d8c01.jpg\" alt=\"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for the <strong>treatment of Chronic Inflammatory Demyelinating Polyneuropathy<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the <strong>Chronic Inflammatory Demyelinating Polyneuropathy market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Types<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mechanism of Action of the Emerging Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Complement C1s inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amyloid beta-protein inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Neonatal Fc receptor antagonists<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Antibody-dependent cell cytotoxicity<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Toll-like receptor 4 antagonists<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomodulators<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regulatory T-lymphocyte replacements<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Segment @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">As per DelveInsight, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population and awareness of CIDP patients in the 7MM. Along with these, the development of advanced technologies will also give robust growth to the market.<\/p>\n<p style=\"text-align: justify;\">The current treatments used on patients with CIDP have some limitations because they are expensive, it is challenging to find the right therapeutic window to balance effectiveness with adverse events (AEs) when using corticoids and immunosuppressive agents, the disease itself is heterogeneous, and some patients are resistant to common medications or develop non-responders over time. Therefore, there is a huge unmet need in the CIDP for drug development.<\/p>\n<p style=\"text-align: justify;\"><em><strong>Currently, Takeda is leading the therapeutics market with its Chronic Inflammatory Demyelinating Polyneuropathy drug candidates in the most advanced stage of clinical development.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Leading Companies in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Market Include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Argenx, Bioasis Technologies, Inc., Biogen Idec, Cellenkos, CSL Behring, GeNeuro SA, Grifols, HarbourBioMed, Immunovant, Johnson &amp; Johnson Services, Kedrion Biopharma, LFB, MedDay Pharmaceuticals, Momenta Pharmaceuticals, Nanjing IASO Biotherapeutics, Nihon Pharmaceutical, OctaPharma, Pfizer, Sanodi, Shire\/ Takeda, Teijin Pharma, UCB Biopharma, and many others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging and Pipeline Therapies Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Batoclimab: Harbour BioMed<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CK0803:Cellenkos<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Efgartigimod: Argenx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HYQVIA: Takeda<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PF-06755347: Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rituximab: Biogen Idec<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rozanolixizumab: UCB S.A.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SAR445088: Sanodi<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Temelimab: GeNeuro SA<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hizentra: CSL Behring<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gamunex-C: Grifols\/Kedrion Biopharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kenketsu Glovenin-I: Nihon Pharmaceutical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Chronic Inflammatory Demyelinating Polyneuropathy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Chronic Inflammatory Demyelinating Polyneuropathy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Chronic Inflammatory Demyelinating Polyneuropathy Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Chronic Inflammatory Demyelinating Polyneuropathy Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Chronic Inflammatory Demyelinating Polyneuropathy Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Chronic Inflammatory Demyelinating Polyneuropathy Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Chronic Inflammatory Demyelinating Polyneuropathy Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Chronic Inflammatory Demyelinating Polyneuropathy Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Chronic Inflammatory Demyelinating Polyneuropathy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/partner-identification-services\">Pharmaceutical Partner Identification Strategies<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-inflammatory-demyelinating-polyneuropathy-cidp-emerging-and-marketed-drugs-assessment-2023-updates-clinical-trials-latest-fda-ema-and-pmda-approvals-key-players-competitive-landscape\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-inflammatory-demyelinating-polyneuropathy-cidp-emerging-and-marketed-drugs-assessment-2023-updates-clinical-trials-latest-fda-ema-and-pmda-approvals-key-players-competitive-landscape\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 10+ key pharma and biotech companies are working on 12+ pipeline drugs in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-emerging-and-marketed-drugs-assessment-2023-updates-clinical-trials-latest-fda-ema-and-pmda-approvals-key-players-competitive-landscape_642634.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,426,417,406,404],"tags":[],"class_list":["post-642634","post","type-post","status-publish","format-standard","hentry","category-Business","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=642634"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642634\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=642634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=642634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=642634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}